Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 212-686-0 | CAS number: 846-48-0
Endpoint summary
Administrative data
Key value for chemical safety assessment
Effects on fertility
Description of key information
No data available.
Additional information
No data available.
Short description of key information:
No data available.
Effects on developmental toxicity
Description of key information
There is no developmental toxicity study with boldenone (ZK 5320) available. However, the result of a teratogenicity study is cited in RTECS database (May 2010):
Subcutaneous (rat, 17.-20. day of pregnancy): TDLo: 20 mg/kg (17-20D preg)
(Advances in the Biosciences. (Pergamon Press Inc., Maxwell House, Fairview Park, Elmsford, NY 10523) V.1- 1967- v. 13, p. 71, 1974 (AVBIB9))
Additional information
There is no developmental toxicity study with boldenone (ZK 5320) available. However, the result of one teratogenicity study is cited in RTECS database (May 2010):
Daily subcutaneous application of boldenone to female rats on day 17 to 20 of pregnancy results in abnormalities of the fetal urogenital system. (Advances in the Biosciences. (Pergamon Press Inc., Maxwell House, Fairview Park, Elmsford, NY 10523) V.1- 1967- v. 13, p. 71, 1974 (AVBIB9))
Toxicity to reproduction: other studies
Additional information
No data available.
Justification for classification or non-classification
Only very limited information on the reproduction toxicity of boldenone (ZK5320) is available. As other anabolic steroids, boldenone has an androgenic activity and long-term uptake of pharmacological doses can result in masculisation, cyclus abnormalities, and impaiment of fertility in women. In men the endogenous hormon production may be impaired, together with disturbed fertility (reduced spermatogenesis). The exposure during pregnancy can result in masculinization of the sexual organs of female fetusses in the womb. When boldenone is taken up by the nursing mother, it may be absorbed with the mothermilk and the development during infancy may be impaired.
Classified according to German legislation (TRGS-905) as Repr. (F) Cat. 1 and Repr. (E) Cat. 2 (EEC criteria).
Classified as Category 1B according toRegulation (EC) 1272/2008 (CLP).
According to the Directive 67/548/EEC, boldenone is classified:
Category 1; R60 - May impair fertility.
Category 2; R61 - May cause harm to the unborn child.
R64 - May cause harm to breastfed babies
Additional information
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
